Shiro Murata Selected Research

Ligands

2/2021	PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma.
1/2018	Cooperation of PD-1 and LAG-3 in the exhaustion of CD4+ and CD8+ T cells during bovine leukemia virus infection.
1/2017	A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
1/2017	Anti-Bovine Programmed Death-1 Rat-Bovine Chimeric Antibody for Immunotherapy of Bovine Leukemia Virus Infection in Cattle.
1/2017	In vitro and in vivo antivirus activity of an anti-programmed death-ligand 1 (PD-L1) rat-bovine chimeric antibody against bovine leukemia virus infection.
8/2014	Expression analysis of programmed death ligand 2 in tumors caused by the avian oncovirus Marek's disease virus.
7/2014	Identification and characterization of bovine programmed death-ligand 2.
1/2014	Expression of PD-L1 on canine tumor cells and enhancement of IFN-γ production from tumor-infiltrating cells by PD-L1 blockade.
5/2012	Increased bovine Tim-3 and its ligand expressions during bovine leukemia virus infection.
5/2012	Molecular characterization of immunoinhibitory factors PD-1/PD-L1 in chickens infected with Marek's disease virus.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shiro Murata Research Topics

Disease

11	Neoplasms (Cancer) 01/2022 - 01/2014
11	Disease Progression 01/2022 - 05/2012
10	Deltaretrovirus Infections (BLV Infection) 01/2022 - 09/2011
9	Persistent Infection 12/2021 - 09/2011
9	Infections 01/2020 - 05/2012
7	Marek Disease (Marek's Disease) 01/2022 - 09/2007
5	Melanoma (Melanoma, Malignant) 01/2022 - 01/2016
5	Paratuberculosis (Johne's Disease) 01/2020 - 01/2016
2	Cattle Diseases (Bovine Diseases) 01/2022 - 07/2014
2	Bacterial Infections (Bacterial Infection) 01/2020 - 01/2019
2	Chronic Disease (Chronic Diseases) 10/2019 - 01/2017
1	Carcinogenesis 11/2021
1	Horse Diseases (Horse Disease) 01/2020
1	Osteosarcoma (Osteogenic Sarcoma) 01/2020
1	Inflammation (Inflammations) 02/2019
1	Virus Diseases (Viral Diseases) 01/2019
1	Anaplasmosis 01/2017
1	Sarcoma (Soft Tissue Sarcoma) 01/2017
1	Lymphocytosis 03/2016
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2016
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016
1	Lymphoma (Lymphomas) 08/2014
1	Coinfection 10/2013
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 06/2013
1	Babesiosis (Piroplasmosis) 10/2012
1	Disease Resistance 08/2012

Drug/Important Bio-Agent (IBA)

11	LigandsIBA 02/2021 - 09/2011
10	B7-H1 AntigenIBA 01/2022 - 09/2011
5	AntibodiesIBA 01/2022 - 01/2016
5	Dinoprostone (PGE2)FDA Link 01/2022 - 01/2018
5	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2011
5	CytokinesIBA 01/2021 - 08/2012
4	AntigensIBA 01/2017 - 01/2014
3	Monoclonal AntibodiesIBA 02/2021 - 01/2017
3	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2020 - 01/2018
3	Messenger RNA (mRNA)IBA 02/2015 - 05/2012
2	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2016
2	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2021 - 01/2020
2	VaccinesIBA 12/2020 - 06/2016
2	Blocking AntibodiesIBA 01/2018 - 01/2017
2	DNA (Deoxyribonucleic Acid)IBA 05/2014 - 09/2007
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2022
1	Interleukin-2 (IL2)IBA 12/2021
1	Transcription Factors (Transcription Factor)IBA 11/2021
1	Oncogene Proteins (Oncogene Protein)IBA 11/2021
1	Protein SIBA 11/2021
1	Biological ProductsIBA 01/2021
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2021
1	Transforming Growth Factor beta (TGF-beta)IBA 01/2021
1	vesatolimodIBA 01/2021
1	Interleukin-10 (Interleukin 10)IBA 01/2020
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2019
1	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2019
1	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2019
1	ProstaglandinsIBA 01/2019
1	Meloxicam (Mobic)FDA LinkGeneric 01/2019
1	Antiviral Agents (Antivirals)IBA 01/2019
1	Interferon-gamma (Interferon, gamma)IBA 01/2018
1	Tuberculin (PPD)IBA 01/2018
1	Immune Checkpoint ProteinsIBA 01/2017
1	PerforinIBA 03/2016
1	Immunoglobulin M (IgM)IBA 08/2014
1	Oligonucleotide ProbesIBA 10/2013
1	Proline (L-Proline)FDA Link 06/2013
1	Histocompatibility Antigens Class IIIBA 01/2013
1	MineralsIBA 10/2012
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 05/2012
1	MucinsIBA 05/2012

Therapy/Procedure

8	Therapeutics 01/2022 - 07/2013
8	Immunotherapy 02/2021 - 09/2011
1	Transjugular Intrahepatic Portasystemic Shunt 09/2007